Show simple item record

AuthorAl-Thani, Alshayma N.
AuthorJan, Asma Ghafoor
AuthorAbbas, Mohamed
AuthorGeetha, Mithra
AuthorSadasivuni, Kishor Kumar
Available date2025-02-16T05:44:25Z
Publication Date2024
Publication NameLife Sciences
ResourceScopus
Identifierhttp://dx.doi.org/10.1016/j.lfs.2024.122899
ISSN243205
URIhttp://hdl.handle.net/10576/63015
AbstractThis comprehensive review provides an in-depth analysis of how nanotechnology has revolutionized cancer theragnostic, which combines diagnostic and therapeutic methods to customize cancer treatment. The study examines the unique attributes, uses, and difficulties linked to different types of nanoparticles, including gold, iron oxide, silica, Quantum dots, Carbon nanotubes, and liposomes, in the context of cancer treatment. In addition, the paper examines the progression of nanotheranostics, emphasizing its uses in precise medication administration, photothermal therapy, and sophisticated diagnostic methods such as MRI, CT, and fluorescence imaging. Moreover, the article highlights the capacity of nanoparticles to improve the effectiveness of drugs, reduce the overall toxicity in the body, and open up new possibilities for treating cancer by releasing drugs in a controlled manner and targeting specific areas. Furthermore, it tackles concerns regarding the compatibility of nanoparticles and their potential harmful effects, emphasizing the significance of continuous study to improve nanotherapeutic methods for use in medical treatments. The review finishes by outlining potential future applications of nanotechnology in predictive oncology and customized medicine.
SponsorThe National Institutes of Health (NIH) and the National Cancer Institute (NCI) also subscribe to the advancement of research work in the safety and efficiency of nanoparticle-based cancer therapeutics through their separate funding initiatives. These organizations finance experiments that establish nanoparticle toxicity, distribution in the body, pharmacokinetics, and clinical translation of those used in the treatment [ 162 ] Worldwide, national agencies like the European Medicines Agency (EMA) and the International Organization for Standardization (ISO) are sponsored to determine standardized protocols and guidelines for the safety of nanoparticles. These activities aim to align the regulatory affairs in different regions and facilitate the acceptance and approval of new nanotherapeutics worldwide.
Languageen
PublisherElsevier
SubjectCancer cells
Diagnostic modalities
Drug delivery
Nanoparticles
Therapeutic functions
TitleNanoparticles in cancer theragnostic and drug delivery: A comprehensive review
TypeArticle Review
Volume Number352
dc.accessType Full Text


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record